

To,
Head, Listing Compliance Department
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001.
Scrip Code: 542650

To,
Head, Listing Compliance Department,
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1. G Block,
Bandra – Kurla Complex, Bandra (East),
Mumbai – 400 051
Scrip Symbol: METROPOLIS

Sub: Intimation of Press Release

Dear Sir/ Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed herewith a Press Release as mentioned below:

Metropolis Healthcare Ltd. records highest ever Non- Covid Revenues at Rs. 288 Crores in Q2FY 23; up to 16% YoY.

You are requested to take the above information on record.

Thanking you,

Yours faithfully

For **Metropolis Healthcare Limited**

Simmi Singh Bisht
Head – Legal and Secretarial
Membership No. A23360

Encl. a/a

BLOOD TESTS • DIAGNOSTICS • WELLNESS

METROPOLIS
The Pathology Specialist

Metropolis Healthcare Limited

Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030.

CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: support@metropolisindia.com

Website: www.metropolisindia.com

Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.

Metropolis Healthcare Ltd. **Records Highest Ever Non-Covid Revenues at Rs. 288 crs in Q2FY23; up by 16% YoY.**

Total B2C Revenue grew by 25% YoY in H1FY23 & 22% in Q2FY23

Q2FY23 Key Highlights

- Wellness revenue increased by 40% YoY to Rs. 33 Crs.
- EBITDA margin (Before CSR & ESOP) stood at 27.6%
- Specialized tests contributed 40% to the Non-Covid revenue

Q2FY23 Key Highlights for Core Business[#]

- Total Revenues grew by 12.4% YoY
- Specialized tests revenues grew by 15% YoY
- Wellness tests revenues grew by 36% YoY
- Patient & Tests volumes grew by 10% YoY

Mumbai, November 8, 2022: Metropolis Healthcare Ltd. (NSE: METROPOLIS | BSE: 542650) - a leading diagnostic service provider - announced its unaudited consolidated financial results today for the second quarter of financial year 2023.

Q2FY23 Financial Highlights

Rs. 288 Crs.

Non Covid Revenue*

Rs. 83 Crs.

EBITDA (Before CSR & ESOP)

Rs. 41 Crs.

Profit After Tax

“I am extremely pleased to share that we have recorded highest ever quarterly revenue* with 16% growth on year-on-year basis. With accelerated shift from the unorganised to the organised sector coupled with increased health awareness amongst customers and a trusted scientific image with medical fraternity, we expect the revenues growth to improve and margins to sustain at the pre-covid levels

We have seen growth in our volumes & patient count and with increased investments in digital & marketing, manpower & customer experience initiatives, we are optimistic of sustaining the growth going forward.

Our revenue contribution from wellness segment has increased to 12% in Q2FY23 & has witnessed a healthy growth of 40% on YoY basis; a testimony to our on-ground efforts and the acceptance of Metropolis Brand in the minds of consumers and medical fraternity.

Ameera Shah, Promoter and Managing Director, Metropolis Healthcare Ltd.

*Revenue excl. covid PCR & covid allied tests #Excluding Hi-tech and Government contracts

ACCREDITATIONS FOR METROPOLIS

The Global Reference Laboratory of Metropolis holds accreditation from the College of American Pathologists (CAP) since 2005 which is the gold standard in accreditations in our industry, globally.

Our clinical laboratories hold one or more of CAP, NABL, KENAS, ILAC or APLAC accreditations.

(CAP: College of American Pathologists; NABL: National Accreditation Board for Testing and Calibration Laboratories; KENAS: Kenya Accreditation Service; ILAC: International Laboratory Accreditation Cooperation, APLAC: Asia Pacific Laboratory Accreditation Cooperation)

RECENT AWARDS AND ACCOLADES

Metropolis honoured with the Best Organizations for Women, 2022 by the Economic Times.

Metropolis Labs in Ghana won the Overall Best Pathology Laboratory Centre of the Year Award at the Ghana Medical Laboratories Excellence Awards (GMLEA).

Metropolis bagged the 'Innovation in Patient Centricity and Advocacy' Award at the Patient First Summit 2022 by IHW (India Health & Wellness Council) for introducing the holistic comprehensive package 'PREGASCREEN'

Metropolis awarded with the 'Most Popular Diagnostic Laboratory Award' at the Healthcare Excellence Awards from CNH Care for demonstrating excellence in customer service based on user reviews.

Metropolis honoured with the 'Best of Bharat – Pride of India Brands' Award from Exchange4media.

Our MD, Ms. Ameera Shah recognized as the Most Promising Women Leader of India 2022 by ET x Femina.

Our MD, Ms. Ameera Shah has been awarded as **EY Entrepreneur of the Year** in Life Science and Healthcare

Our CFO Mr. Rakesh Agarwal was felicitated with the '**Financial Star**' Award at the debut edition of the Financial Express' CFO Connect Conclave for his exemplary contribution in the field of Finance and to the growth of the organization.

Dr. Kirti Chadha, Chief Scientific Officer and Group Head – CSR recognized with the **Distinguished Doctor of the Year Award in Oncopathologist category** by Assocham for her outstanding contribution in healthcare industry.

In INR Crs.	Q2FY23	Q2FY22	Q1FY23
Revenue from Operations	300.3	302.6	279.9
EBIDTA (before CSR & ESOP)	83.0	93.2	71.7
EBIDTA margin (before CSR & ESOP)	27.6%	30.8%	25.6%
Profit After Tax	40.5	58.4	33.6
PAT Margin (%)	13.5%	19.3%	12.0%

About Metropolis: Established in 1981, Metropolis Healthcare Limited is a leading diagnostics company in India with a widespread presence in 20 states & 220 cities. Internationally, the company has presence in South Asia, Africa, and the Middle East. Metropolis touches millions of lives each year by providing actionable health insights to patients and doctors. Metropolis offers a comprehensive range of 4,000 plus tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases, and an array of genetic abnormalities. The company is empowered with a robust network of over 172 labs, 3379 collection centres and 10000+ touch points. Metropolis' commitment to quality and accuracy in each test is reinforced by its consistent CAP proficiency score of more than 98% over the past decade, which places it amongst the top 1% laboratories worldwide for quality assurance. Metropolis philosophy rests on the pillars of technological superiority, a warm patient centric approach and reliable diagnostic reports. For more information, please visit www.metropolisindia.com or click on [Twitter](#), [Facebook](#), or [LinkedIn](#).

Safe harbor statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further details please contact:

Company: Metropolis Healthcare Ltd.

CIN -L73100MH2000PLC192798

Mr. Jeyasingh Balakrishnan – Head - Corporate Communications

jeyasingh.b@metropolisindia.com

www.metropolisindia.com

Investor Relations Advisors: Strategic Growth Advisors Pvt. Ltd.

CIN: U74140MH2010PTC204285

Mr. Shogun Jain / Mr. Sagar Shroff

+91 77383 77756 / +91 98205 19303

shogun.jain@sgapl.net / sagar.shroff@sgapl.net